Casanthranol
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412423

CAS#: 8024-48-4

Description: Casanthranol is dried aged bark of a buckthorn, Frangula purshiana ( FRANGULA), that contains the anthraquinone EMODIN and cascarosides. It is used as a laxative ( CATHARTICS).


Chemical Structure

img
Casanthranol
CAS# 8024-48-4

Theoretical Analysis

MedKoo Cat#: 412423
Name: Casanthranol
CAS#: 8024-48-4
Chemical Formula: C21H22O10
Exact Mass: 434.1213
Molecular Weight: 434.39
Elemental Analysis: C, 58.06; H, 5.11; O, 36.83

Price and Availability

Size Price Availability Quantity
50.0g USD 225.6 2 Weeks
Bulk inquiry

Synonym: Casanthranol; UNII-3SJ3U7J6V2; DOCUSATE SODIUM

IUPAC/Chemical Name: (R)-1,8-dihydroxy-3-(hydroxymethyl)-10-(((2R,3R,4R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)anthracen-9(10H)-one

InChi Key: CPUHNROBVJNNPW-VVBPCJSVSA-N

InChi Code: InChI=1S/C21H22O10/c22-6-8-4-10-15(12(25)5-8)17(27)14-9(2-1-3-11(14)24)20(10)31-21-19(29)18(28)16(26)13(7-23)30-21/h1-5,13,16,18-26,28-29H,6-7H2/t13-,16+,18-,19-,20-,21+/m1/s1

SMILES Code: OC[C@H]1O[C@H]([C@@H]([C@@H]([C@H]1O)O)O)O[C@@H]2c3c(C(c4c2cc(CO)cc4O)=O)c(O)ccc3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 434.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Edenfield AL, Siddiqui NY, Wu JM, Dieter AA, Garrett MA, Visco AG. Polyethylene Glycol 3350 and Docusate Sodium Compared With Docusate Sodium Alone After Urogynecologic Surgery: A Randomized Controlled Trial. Obstet Gynecol. 2016 Sep;128(3):543-9. doi: 10.1097/AOG.0000000000001565. PMID: 27500338.

2: Ruston T, Hunter K, Cummings G, Lazarescu A. Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to PEG in opioid-induced constipation: a systematic review. Can Oncol Nurs J. 2013 Autumn;23(4):236-46. English, French. doi: 10.5737/1181912x234236240. PMID: 24428006.

3: MacMillan TE, Kamali R, Cavalcanti RB. Missed Opportunity to Deprescribe: Docusate for Constipation in Medical Inpatients. Am J Med. 2016 Sep;129(9):1001.e1-7. doi: 10.1016/j.amjmed.2016.04.008. Epub 2016 May 3. PMID: 27154771.

4: Docusate sodium. Nurs Times. 2005 Mar 29-Apr 4;101(13):33. PMID: 15819494.

5: Nader ME, Saliba I. Ototoxicity of intratympanic docusate sodium and mineral oil in the guinea pig. Otolaryngol Head Neck Surg. 2012 Mar;146(3):455-60. doi: 10.1177/0194599811429255. Epub 2011 Nov 18. PMID: 22101097.

6: Tarumi Y, Wilson MP, Szafran O, Spooner GR. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manage. 2013 Jan;45(1):2-13. doi: 10.1016/j.jpainsymman.2012.02.008. Epub 2012 Aug 11. PMID: 22889861.

7: McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther. 1998 May;12(5):491-7. doi: 10.1046/j.1365-2036.1998.00336.x. PMID: 9663731.

8: Fakheri RJ, Volpicelli FM. Things We Do for No Reason: Prescribing Docusate for Constipation in Hospitalized Adults. J Hosp Med. 2019 Feb;14(2):110-113. doi: 10.12788/jhm.3124. PMID: 30785419.

9: Akinboyo IC, Sick-Samuels AC, Singeltary E, Fackler J, Ascenzi J, Carroll KC, Maldonado Y, Brooks RB, Benowitz I, Wilson LE, LiPuma JJ, Milstone AM. Multistate Outbreak of an Emerging Burkholderia cepacia Complex Strain Associated With Contaminated Oral Liquid Docusate Sodium. Infect Control Hosp Epidemiol. 2018 Feb;39(2):237-239. doi: 10.1017/ice.2017.265. PMID: 29417919; PMCID: PMC5837050.

10: Singer AJ, Sauris E, Viccellio AW. Ceruminolytic effects of docusate sodium: a randomized, controlled trial. Ann Emerg Med. 2000 Sep;36(3):228-32. doi: 10.1067/mem.2000.109166. PMID: 10969225.